We aimed to examine whether doses of melphalan higher than 200 mg/m 2 improve response rates when used as conditioning before autologous transplant (ASCT) in multiple myeloma (MM) patients. Patients with MM, n = 131, were randomized to 200 mg/m 2 (mel200) vs 280 mg/m 2 (mel280) using amifostine pretreatment. The primary end point was the proportion of patients achieving near complete response (⩾ nCR). No treatment-related deaths occurred in this study. Responses following ASCT were for mel200 vs mel280, respectively, ⩾ nCR 22 vs 39%, P = 0.03, ⩾ PR 57 vs 74%, P = 0.04. The hazard of mortality was not statistically significantly different between groups (mel200 vs mel280; hazard ratio (HR) = 1.15 (95% confidence interval (CI), 0.62-2.13, P = 0.66)) nor was the rate of progression/mortality (HR = 0.81 (0.52-1.27, P = 0.36)). The estimated PFS at 1 and 3 years were 83 and 46%, respectively, for mel200 and 78 and 54%, respectively, for mel280. Amifostine and mel280 were well tolerated, with no grade 4 regimen-related toxicities and only one grade 3 mucositis (none with mel200) and three grade 3 gastrointestinal (GI) toxicities (two in mel200). Hospitalization rates were more frequent in the mel280 group (59 vs 43%, P = 0.08). Mel280 resulted in a higher major response rate (CR+nCR) and should be evaluated in larger studies.
INTRODUCTION
High-dose chemotherapy followed by transfusion of autologous stem cells (ASCT) has become an important treatment option for suitable patients with multiple myeloma (MM). This is due to a series of prospective trials comparing ASCT as consolidation after conventional therapy induction demonstrating improved response rates, greater PFSs and in some but not all studies, improved OS. [1] [2] [3] [4] [5] The dose of melphalan, 200 mg/m 2 , was established from early trials demonstrating unacceptable gastrointestinal toxicity at higher doses. 6 Single-agent high-dose melphalan has remained the standard regimen for patients with myeloma who undergo ASCT due to the paucity of trials comparing melphalan 200 mg/m 2 with other chemotherapy regimens or melphalan with added TBI. A single comparison trial has shown that adding TBI to melphalan is inferior to melphalan 200 mg/m 2 with respect to OS. 7 The cytoprotective drug amifostine is approved by the FDA for preventing platinum-associated nephrotoxicity and xerostomia associated with head and neck irradiation. Retrospective and prospective trials of amifostine have shown a reduction in gastrointestinal toxicities caused by melphalan 200 mg/m 2 when given before ASCT. 8, 9 In a phase 1 dose-escalation trial, amifostine was shown to protect patients from the gastrointestinal toxicities of melphalan given in doses as high as 280 mg/m 2 followed by ASCT. 10 A phase 2 trial utilizing amifostine and a fixed dose of melphalan 280 mg/m 2 followed by ASCT reported no serious gastrointestinal toxicities and a complete response (CR) rate of 55%.
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With this background we conducted a prospective, randomized, multicenter trial comparing melphalan 200 mg/m 2 with melphalan 280 mg/m 2 for patients with MM who were candidates for ASCT. We hypothesized that the higher dose of melphalan could improve response rates with the potential to improve outcomes.
MATERIALS AND METHODS
This prospective trial was designed to compare response rates after highdose melphalan 200 mg/m 2 or 280 mg/m 2 used before ASCT in patients with MM. The primary end point was the rate of near complete response (nCR) or better between the groups as defined by modified criteria reported by Blade. 12 nCR is defined as the absence of measurable monoclonal proteins by serum or urine electrophoresis but still detectable by immunofixation, less than 5% plasma cells by bone marrow histology, no new bone lesions or progression of existing lesion on skeletal survey and normal calcium. Secondary end points included overall response rates, grade 3-4 toxicities defined by NCI CTCAE v3.0, incidence and length of hospitalizations, OS and PFS. Partial response after transplant required a 50% reduction in monoclonal protein from pre-transplant levels. Eligibility criteria included symptomatic MM requiring therapy, measurable disease consisting of at least 0.2 g/dL monoclonal protein in serum or at least 200 mg Bence-Jones protein per 24 h in urine, Eastern Cooperative Oncology Group performance status of 2 or less, cardiac ejection fraction of at least 50%, CO 2 diffusion capacity of at least 50%, total bilirubin o2 mg/dL, gamma-glutamyl transpeptidase o2.5 times upper limit of normal and an estimated or measured creatinine clearance of 460 ml/min. Patients with non-secretory, serum light chain only and patients in ⩾ nCR were excluded. Specifically, patients with a monoclonal protein of 0.1 g/dL 1 13 Cryopreserved PBSC were thawed and infused 2 days after melphalan per local institutional guidelines. Standard transfusion and antibiotic support measures were utilized at each Center. Engraftment of neutrophils was defined as the first of 2 consecutive days 45 ×10 8 /L. Engraftment of platelets was the first of 7 consecutive days 420 × 10 9 /L without transfusion. Between 70 and 100 days after ASCT, patients were restaged with a marrow aspiration, skeletal survey, calcium level, serum protein electrophoresis and 24-h urine collection for quantitative Bence-Jones protein.
The study was designed to have 80% power to observe a statistically significant difference (at the two-sided significance level of 0.05) in the probabilities of ⩾ nCR, where the assumed-true probabilities of ⩾ nCR were 0.30 and 0.55 for mel200 and mel280, respectively. Probabilities of response, toxicity and hospitalization were compared with the chi-square test, and OS and PFS were summarized using Kaplan-Meier estimates. The hazards of failure for both OS and PFS were compared using Cox regression. Duration of hospitalization was compared with the ranksum test.
This trial (NCT00217438) opened for enrollment September 2005 and completed enrollment in June 2012. Patients were enrolled at four centers; The University of Washington, Seattle, the Veterans Administration Hospital, Seattle, the Cedars Sinai Medical Center, Los Angeles and the James Wilmot Cancer Center in Rochester, NY. The protocol and consent forms were approved by local IRB's at each participating center. All patients signed the approved informed consent.
RESULTS
Of 134 patients who consented to this study, 1 patient did not meet the inclusion criteria and 2 declined to participate. A total of 131 patients were randomized which met pre-defined accrual, closing the study. Outcomes are reported by intention-to-treat once patients were randomized. Patient characteristics are shown in Table 1 . They were well matched for age, gender, race and number of prior treatments. The median times from diagnosis to ASCT were 9.5 months in the mel280 group vs 9.0 months in the mel200 group. Table 2 includes additional information on timing of transplant, prior use of novel drugs for induction and details on maintenance therapy. The majority of patients (77-79%) received transplant as consolidation after 1-2 induction regimens. Almost all of the patients received induction therapy with one or more novel agents; more patients in the mel200 group received lenalinomide as part of their initial therapies. Less than half of the patients received maintenance therapy after ASCT; 43% in the Mel200 group vs 47% in the Mel280 group.
Toxicities from amifostine infusion Infusional toxicities were generally manageable with hydration and premedication with ranitidine, dexamethasone, ondansetron and diphenhydramine. Grades 1-2 hypotension, nausea and flushing were common expected toxicities, except for the grade 3 hypotensive episode occurring in one patient withdrawn from study (this patient is analyzed as randomized, however). Among all patients randomized, toxicities are shown in Table 3 .
Toxicities and hospitalization after melphalan and ASCT Patients who received mel280 tended to have more grades 2-3 mucositis (33% (95% CI, 22-45%) vs 12% (95% CI, 4-20%), P = 0.004). There were also more grade 2-3 gastrointestinal toxicities in the mel280 group but the difference was not statistically significant (21% (95% CI, 11-31%) vs 12% (95% CI, 4-10%), P = 0.17). Twenty-four of the sixty-six (36% (95% CI, 25-48%) mel280 patients had at least one grade 2-3 toxicity compared with 14 of 65 (22% (95% CI, 12-32%)) patients in the mel200 group, P = 0.06. More patients were hospitalized who received mel280, although the frequency was not statistically significantly (59% (95% CI, 47-71%) vs 43% (95% CI, 31-55%), P = 0.08) but the duration of hospitalization was longer in the mel280 group (median 6 days vs 0 days, P = 0.02) Table 4 . Engraftment The Mel280 group had ANC engraftment slightly faster than Mel200 (median 14 days vs 15 days; mean 14.0 days vs 16.5 days), P = 0.006 (Wilcoxon rank-sum test). The time to platelet engraftment was similar (median 10 days both; mean 11.0 Mel200 vs mean 11.6 Mel280), P = 0.44 (rank-sum).
Platelet requirements were higher in the Mel280 group (median 6 for both; mean 9.7 in Mel280 vs mean 6.6 in Mel200), P = 0.03 (rank-sum test) RBC requirements were a bit higher in the Mel280 group but not statistically significantly higher (median 2 both; mean 2.3 in Mel280 vs mean 2.0 in Mel200), P = 0.17 (rank-sum test).
No deaths occurred during the transplant and recovery phase in either group.
Response after ASCT Among the group receiving mel280 26 of 66 patients achieved ⩾ nCR (39.4% (95% CI, 28.5-51.5%) compared with 14 of 65 patients receiving mel200 (22.2% (95% CI, 13.2-33.1%)), P = 0.03. The overall response rates were 74.2% (95% CI, 62.5-83.3%) for mel280 vs 56.9% (95% CI, 44.8-68.2%) for mel200, P = 0.04, Table 5 .
The median follow-up among survivors is 3.3 years (range 0.5-8.7) in the mel200 group and 3.0 years (range 0.3-8.2) in the mel280 group. The median PFS is 2.7 years and 3.5 years, respectively, and the median OS is 5.3 years and 6.2 years, respectively. There was no statistically significant difference in the hazard rate for failure (death or relapse) between patients Abbreviations: CR = complete response; MR = minimal response; nCR = near complete response; PD = progressive disease; PR = partial response; SD = stable disease. Years after transplant Probability of survival Mel280 -------Mel200 Figure 2 . OS between patients receiving mel200 and mel280. (Figure 1 ). The hazard of overall mortality was similarly not statistically significantly different between patients receiving mel200 and mel280; HR = 1.15 (95% CI 0.62-2.13, P = 0.66) (Figure 2 ). DISCUSSION High-dose melphalan followed by ASCT remains a standard of care for suitable patients with MM. This approach leads to improved response rates, PFS and OS, but few if any patients are actually cured by ASCT. Despite several attempts there has been little progress in improving conditioning regimens for patients who are candidates for ASCT. One prospective trial comparing single-agent melphalan with melphalan plus TBI observed similar PFSs but superior OS for single-agent melphalan. 7 Retrospective studies have suggested that some regimens such as BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) may improve outcomes when compared with patients with myeloma receiving single-agent melphalan but these have not been validated prospectively.
14 In several reports, the combination of busulfan and melphalan have been used for conditioning before ASCT with high response rates and median PFS of 41-48 months, Although case-matched comparisons with melphalan suggest longer PFS, no prospective trials have been reported. 15, 16 Other studies have examined adding myeloma-specific drugs such as bortezomib to high-dose melphalan. 17, 18 These studies suggest higher initial response rates but no long-term outcomes or randomized comparison trials have been reported.
Yet another approach to improving outcomes after ASCT for patients with MM has been to employ sequential cycles of highdose melphalan spaced 3-6 months apart. In randomized trials tandem ASCT can improve OS by about 10% compared with single ASCT. 19, 20 This effect is small because patients who relapse after a single ASCT can receive a salvage ASCT. Almost paradoxically, however, two studies have shown that the survival benefit of a second ASCT occurs mainly in patients who do not achieve a major response to their first transplant, while patients who are already in CR do not benefit from a second ASCT.
The present study validated the potential for dose-escalated melphalan 280 mg/m 2 to improve responses. Since melphalan has been shown to require active transport into mouse leukemia cells, much higher doses could theoretically overwhelm this system and limit tumor cell cytotoxicity. 21 Our study was not designed to examine this possibility but very high doses of melphalan could alternatively improve intracellular diffusion of drug exclusive of the active transport mechanisms. While the improved responses did not improve PFS or OS, the study was neither designed nor powered to show statistically significant differences in PFS or OS. This outcome is not different from two recently published randomized trials of initial therapy comparing bortezomib, dexamethasone (VD) with vincristine, adriamycin, dexamethasone (VAD) and a trial comparing VD plus thalidomide (VTD) with thalidomide and dexamethasone (TD). 22 Despite significantly higher rates of nCR and ORR with VD or VTD induction both before and after ASCT, and more than 3 times the number of patients enrolled in our study, only one study showed a difference in PFS and neither study showed an OS difference. In order to measure the rates of major response the current study excluded patients who were already in CR or nCR before ASCT. This may have biased the study toward a group of patients with more resistant disease who in turn would tend to have shorter lengths of remission. There were more patients with grades 2-3 mucositis in the mel280 group but no statistically significant difference in grades 2-3 gastrointestinal toxicity. There were no observed episodes of grade 4 mucositis in this study and only one episode of grade 3 mucositis (in the mel280 arm). This appears to be considerably lower than reports of oral mucositis in other studies which have ranged from 21 to 46%. 23, 24 This is likely the result of the combined use of ice chips and amifostine. We did observe a longer length of hospitalization in the mel280 group. This did not result in more transplant-related deaths, in fact, there were no patients who died of complications of transplant in the entire study.
This trial has demonstrated that amifostine can limit the toxicities associated with melphalan given at 280 mg/m 2 . This higher dose of melphalan can result in improved response rates. Whether this approach can improve PFS or OS would require a much larger, prospective randomized trial. Such a study would need to enroll approximately 450 patients to demonstrate a 6-month difference between melphalan 280 mg/m 2 and 200 mg/m 2 in PFS that would be statistically significant. It would not be necessary to exclude patients already in CR or nCR since the primary end point would be PFS. Although other promising agents such a bortezomib could be added to such a study, this would make the trial more complex and likely increase the study size.
